aTyr Faces Securities Suit After Phase 3 Failure Triggers 83% Stock Crash

Overview

• The federal case, Munguia v. aTyr Pharma Inc., was filed in the U.S. District Court for the Southern District of California.
• Plaintiffs claim executives made overly positive statements about Efzofitimod’s steroid‑taper potential while concealing adverse information tied to the EFZO-FIT design.
• The proposed class covers purchasers from January 16, 2025 through September 12, 2025, with a lead‑plaintiff motion deadline of December 8, 2025.
• Hagens Berman, Bronstein Gewirtz & Grossman, and Rosen Law Firm have announced actions or investigations and are soliciting investors and potential whistleblowers.
• aTyr disclosed on September 15 that EFZO-FIT failed its primary endpoint—change in mean daily oral corticosteroid dose at week 48 in pulmonary sarcoidosis—and said it would consult the FDA on next steps.